The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2023 | The benefits of determining front-line therapy in NSCLC with liquid biopsies
Luis Raez, MD, FACP, FCCP, Memorial Healthcare System, Pembroke Pines, FL, compares the utility of liquid and tissue biopsies to assess front-line therapies in patients with non-small cell lung cancer (NSCLC). Liquid biopsies can be processed quicker than tissue biopsies, where they can be analyzed in smaller clinics and hospitals with fewer resources. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
